Neuromuscular Disorders
Volume 16, Issue 6 , Pages 396-402 , June 2006

136th ENMC International Workshop: Charcot–Marie–Tooth Disease Type 1A (CMT1A)8–10 April 2005, Naarden, The Netherlands

  • M.M. Reilly

      Affiliations

    • Centre for Neuromuscular Disease and Department of Molecular Neurosciences, Institute of Neurology, National Hospital for Neurology and Neurosurgery and Institute of Neurology, Queen Square, London, UK
    • ,
  • P. de Jonghe

      Affiliations

    • Department of Molecular Genetics, Flanders Interuniversity Institute for Biotechnology and Division of Neurology, University of Antwerp, Antwerp, Belgium
    • ,
  • D. Pareyson

      Affiliations

    • Division of Biochemistry and Genetics, ‘C. Besta’ National Neurological Institute, Via Celoria 11, 20133 Milan, Italy
    • Corresponding Author InformationCorresponding author.

Received 17 February 2006

References 

  1. Nelis E, Van Broeckhoven C, De Jonghe P, et al. Estimation of the mutation frequencies in Charcot–Marie–Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet. 1996;4:25–33
  2. Sereda MW, Meyer zu Horste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone antagonist in a model of Charcot–Marie–Tooth disease (CMT-1A). Nat Med. 2003;9:1533–1537
  3. Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot–Marie–Tooth disease. Nat Med. 2004;10:396–401
  4. Raeymaekers P, Timmerman V, Nelis E, et al. Duplication in chromosome 17p11.2 in Charcot–Marie–Tooth neuropathy type 1a (CMT 1a). The HMSN collaborative research group. Neuromuscul Disord. 1991;1:93–97
  5. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, et al. DNA duplication associated with Charcot–Marie–Tooth disease type 1A. Cell. 1991;66:219–232
  6. Sereda M, Griffiths I, Puhlhofer A, et al. A transgenic rat model of Charcot–Marie–Tooth disease. Neuron. 1996;16:1049–1060
  7. Huxley C, Passage E, Manson A, et al. Construction of a mouse model of Charcot–Marie–Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet. 1996;5:563–569
  8. Young P, Suter U. Disease mechanisms and potential therapeutic strategies in Charcot–Marie–Tooth disease. Brain Res Brain Res Rev. 2001;36:213–221
  9. Perea J, Robertson A, Tolmachova T, et al. Induced myelination and demyelination in a conditional mouse model of Charcot–Marie–Tooth disease type 1A. Hum Mol Genet. 2001;10:1007–1018
  10. Merkies IS, Schmitz PI, van der Meché FG, Samijn JP, van Doorn PA, for the inflammatory neuropathy cause and treatment (INCAT) group . Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry. 2002;72:596–601
  11. Holman R, Lindeboom R, Vermeulen M, de Haan RJ. The AMC Linear disability score project in a population requiring residential care: psychometric properties. Health Qual Life Outcomes. 2004;2:42
  12. Shy M, Blake J, Krajewski K, Fuerst D, Laura M, Reilly MM. CMT Neuropathy score: a valid measure of disability. Neurology. 2005;64:1209–1214
  13. Merlini L, Mazzone E, Solari A, Morandi L. Reliability of hand-held dynamometry in spinal muscular atrophy. Muscle Nerve. 2002;26:64–70
  14. Kilmer BDD, McCrory MA, Wright NC, Rosko RA, Kim HR, Aitkens SG. Hand-held dynamometry reliability in persons with neuropathic weakness. Arch Phys Med Rehabil. 1997;78:1364–1368
  15. Hughes R, Bensa S, Willison H, et al. Inflammatory neuropathy cause and treatment (INCAT) group. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:195–201
  16. Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory neuropathy cause and treatment (INCAT) group. Neurology. 2000;54:943–949
  17. Ware JE, Sherbourne C. The MOS 36-items short-form survey (SF-36): I. Conceptual framework and items selection. Med Care. 1992;30:473–483
  18. Li J, Bai Y, Ghandour K, et al. Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain. 2005;128:1168–1177
  19. Gallardo E, Garcia A, Combarros O, et al. Charcot–Marie–Tooth disease type 1A duplication: spectrum of clinical and magnetic resonance imaging features in leg and foot muscles. Brain. 2006;129:426–437
  20. Ellegala DB, Monteith SJ, Haynor D, Bird TD, Goodkin R, Kliot M. Characterization of genetically defined types of Charcot–Marie–Tooth neuropathies by using magnetic resonance neurography. J Neurosurg. 2005;102:242–245
  21. Dietary reference intakes, The National Academies Press, Washington DC, USA; 2000.
  22. Levine M, Country-Cantilena C, Wang Y, et al. Vitamin C pharmakocinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Nat Acad Sci. 1996;93:3704–3709
  23. Hathcock JN, Azzi A, Blumberg J, et al. Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr. 2005;81:736–745

PII: S0960-8966(06)00094-0

doi: 10.1016/j.nmd.2006.03.008

Neuromuscular Disorders
Volume 16, Issue 6 , Pages 396-402 , June 2006

Article Tools